Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CPCatalyst Pharmaceuticals, Inc. logo

Catalyst Pharmaceuticals, Inc. (CPRX)

NASDAQ Capital Market · Currency in USD
$31.49 ▲ +0.00 (+0.00%)
At close: Jul 15, 9:30 AM ET. Market closed.

Summary

Previous Close
$31.49
Open
$31.49
Day's Range
$31.49 – $31.49
52 Week Range
$19.05 – $32.56
Volume
0
Avg. Volume
3,010,030
Market Cap
$3.85B
Beta (5Y Monthly)
0.74
PE Ratio (TTM)
17.49
EPS (TTM)
$1.81
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$31.75

Profile: Catalyst Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
182
CEO
Richard John Daly

Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS).

Earnings

DateEst.Actual
May 11, 2026$0.64$0.52Miss
Feb 25, 2026$0.42$0.42Beat
Nov 5, 2025$0.51$0.43Miss
Aug 6, 2025$0.58$0.43Miss
May 7, 2025$0.53$0.47Miss
Feb 26, 2025$0.32$0.47Beat

Analyst view

Consensus price target
$31.75 ▲ +0.8%
Range $31.50 – $32.00
Rating: Buy
Buy 75% · Hold 25% · Sell 0%

Get free alerts on CPRX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.